Table 2.
Characteristics of HIV-Infected Patients with and without Leptospirosis, Northern Tanzania, 2007–2008
| HIV-infected with leptospirosis n=9 | HIV-infected without leptospirosis n=194 | Odds ratio | p value | |
|---|---|---|---|---|
| Median age (range) years | 31.4 (1.8, 58.5) | 34.5 (0.2, 73.0) | — | 0.287 |
| Median CD4 (range) cells/μLa | 335 (86, 1105) | 123 (1, 2316) | — | 0.034 |
| Median CD4 (range) cells/μL, for adults and adolescents onlyb | 203 (86, 1105) | 99 (1, 813) | — | 0.089 |
| Median CD4 percent (range)c | 20 (4,45) | 9 (0,56) | — | 0.019 |
| Median CD4 percent (range), for adults and adolescents onlyd | 18 (11, 45) | 8 (0, 43) | — | 0.015 |
| Severe immunosuppressiona | 3/8 (37.5%) | 102/188 (54.3%) | 0.52 | 0.476 |
| Prescribed ART | 5/8 (62.5%) | 55/144 (38.2%) | 2.70 | 0.265 |
| Prescribed SXT prophylaxise | 3/6 (50.0%) | 48/143 (33.6%) | 1.98 | 0.412 |
a
n=8 for HIV-infected with leptospirosis; n=188 for HIV-infected without leptospirosis.
b
n=5 for HIV-infected with leptospirosis; n=142 for HIV-infected without leptospirosis.
c
n=8 for HIV-infected with leptospirosis; n=180 for HIV-infected without leptospirosis.
d
n=5 for HIV-infected with leptospirosis; n=136 for HIV-infected without leptospirosis.
e
n=6 for HIV-infected with leptospirosis; n=143 for HIV-infected without leptospirosis.
HIV, human immunodeficiency virus; ART, antiretroviral therapy; SXT, trimethoprim-sulfamethoxazole.